CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis

Julià, Antonio, Gómez, Antonio, López-Lasanta, María, Blanco, Francisco, Erra, Alba, Fernández-Nebro, Antonio, Mas, Antonio Juan, Pérez-García, Carolina, Vivar, Ma Luz García, Sánchez-Fernández, Simón, Alperi-López, Mercedes, Sanmartí, Raimon, Ortiz, Ana María, Fernandez-Cid, Carlos Marras, Díaz-Torné, César, Moreno, Estefania, Li, Tianlu, Martínez-Mateu, Sergio H., Absher, Devin M., Myers, Richard M., Molina, Jesús Tornero, Marsal, Sara·2022·eBioMedicine
DOI 10.1016/j.ebiom.2022.104053PMC PMC9118662
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2022.104053

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Principal component analysis (PCA) of the RA and healthy control cohort. PCA revealed a group of individuals showing an outlier methylation profile. (a). Clustering analysis using the Partitioning Around Medoids implemented in M3C software supported the presence of two groups of individuals showing significantly different methylation profile. The x-axis indicates each of the clustering partitions evaluated (k=2 to 10); k=2 (orange dot) showed a highly significant evidence for clustering (P<0.001). (b). Principal components of the RA and control cohort showing the outlier group of individuals in the second PC, and color-coded based on the M3C k=2 class assignments.
Figure 1 Principal component analysis (PCA) of the RA and healthy control cohort. PCA revealed a group of individuals showing an outlier methylation profile. (a). Clustering analysis using the Partitioning Around Medoids implemented in M3C software supported the presence of two groups of individuals showing significantly different methylation profile. The x-axis indicates each of the clustering partitions evaluated (k=2 to 10); k=2 (orange dot) showed a highly significant evidence for clustering (P<0.001). (b). Principal components of the RA and control cohort showing the outlier group of individuals in the second PC, and color-coded based on the M3C k=2 class assignments.CC BY-NC-ND · PubMed Central
Figure 2 Schematic representation of the analytical design used to identify methylation variation associated with TNFi response. (a). Using blood methylation data from a large case-control cohort, the biological pathways associated with RA were identified (n=246). Using these disease-linked pathways, we were able to identify biological processes that are modified by TNFi treatment in longitudinal cohort of RA patients starting therapy (n=62). Also, pathways associated with the response to therapy at week 12 were identified. Using an independent patient cohort (n=59), the findings could be validated. (b). Using a novel cell-deconvolution approach in the discovery and validation cohorts, we were able to identify differentially methylated positions in multiple immune cell types associated with the response to TNFi. Monocytes showed the larger number of validated associations and we conducted TF motif enrichment to characterize the principal differentiation programs associated with response in this innate immune cell type.
Figure 2 Schematic representation of the analytical design used to identify methylation variation associated with TNFi response. (a). Using blood methylation data from a large case-control cohort, the biological pathways associated with RA were identified (n=246). Using these disease-linked pathways, we were able to identify biological processes that are modified by TNFi treatment in longitudinal cohort of RA patients starting therapy (n=62). Also, pathways associated with the response to therapy at week 12 were identified. Using an independent patient cohort (n=59), the findings could be validated. (b). Using a novel cell-deconvolution approach in the discovery and validation cohorts, we were able to identify differentially methylated positions in multiple immune cell types associated with the response to TNFi. Monocytes showed the larger number of validated associations and we conducted TF motif enrichment to characterize the principal differentiation programs associated with response in this innate immune cell type.CC BY-NC-ND · PubMed Central
Figure 3 Clustering of pathways associated with RA. Comparing the methylation profile of n=301 patients and n=305 healthy individuals, a total of 246 biological processes were found to be associated with RA using gometh. In this heatmap, the associated GO terms (rows and columns) are clustered according to their similarity based on Lin's measure [38]. The terms are then hierarchically clustered using complete linkage, and the tree is cut at the desired threshold (here 0.7). For each resulting cluster, the biological process showing the most significant association with RA was chosen as the representative biological function (right legend). A total of n=20 pathway clusters were identified associated with RA.
Figure 3 Clustering of pathways associated with RA. Comparing the methylation profile of n=301 patients and n=305 healthy individuals, a total of 246 biological processes were found to be associated with RA using gometh. In this heatmap, the associated GO terms (rows and columns) are clustered according to their similarity based on Lin's measure [38]. The terms are then hierarchically clustered using complete linkage, and the tree is cut at the desired threshold (here 0.7). For each resulting cluster, the biological process showing the most significant association with RA was chosen as the representative biological function (right legend). A total of n=20 pathway clusters were identified associated with RA.CC BY-NC-ND · PubMed Central
Figure 4 RA pathway association with TNFi response. A. Percentage of pathways linked to RA (n=246) that were significantly associated to the discovery cohort (left bar plots). From these, the middle bar plots indicate the percentage of significantly validated pathways in the validation cohort. Finally, the right bar plots show the percentage of validated pathways that have consistent methylation changes between the two patient cohorts using the resampling-based test. wk0: pathways associated with TNFi response at week 0; wk12: pathways associated with TNFi response at week 12; wk12 vs wk0: pathways changing from week 0 to week 12 of TNFi therapy; R vs NR: pathways showing longitudinal methylation differences between responders and non-responders to TNFi therapy. B. Association results in the validation cohort of the RA pathways associated with TNFi response at week 0 in the discovery cohort. Four pathways were found to be significantly replicated (red bars, FDR < 0.05). C. Association results in the validation cohort of the RA pathways associated with TNFi response at week 12 in the discovery cohort. One pathway, regulation of small GTPase signal transduction was found to be significantly replicated (red bar, FDR < 0.05).
Figure 4 RA pathway association with TNFi response. A. Percentage of pathways linked to RA (n=246) that were significantly associated to the discovery cohort (left bar plots). From these, the middle bar plots indicate the percentage of significantly validated pathways in the validation cohort. Finally, the right bar plots show the percentage of validated pathways that have consistent methylation changes between the two patient cohorts using the resampling-based test. wk0: pathways associated with TNFi response at week 0; wk12: pathways associated with TNFi response at week 12; wk12 vs wk0: pathways changing from week 0 to week 12 of TNFi therapy; R vs NR: pathways showing longitudinal methylation differences between responders and non-responders to TNFi therapy. B. Association results in the validation cohort of the RA pathways associated with TNFi response at week 0 in the discovery cohort. Four pathways were found to be significantly replicated (red bars, FDR < 0.05). C. Association results in the validation cohort of the RA pathways associated with TNFi response at week 12 in the discovery cohort. One pathway, regulation of small GTPase signal transduction was found to be significantly replicated (red bar, FDR < 0.05).CC BY-NC-ND · PubMed Central
Figure 5 Directionality test results for pathway methylation changes induced by TNFi. Profile plot showing the percentage of CpGs having opposite methylation changes between disease development (i.e. RA vs controls) and the response to TNFi (i.e. week12 vs baseline) for the pathways linked with RA. The top 40 pathways showing the strongest significant statistical evidence are included in the plot. These results confirm the effect of blood methylation variation induced by TNFi, clearly reversing it towards that of healthy individuals.
Figure 5 Directionality test results for pathway methylation changes induced by TNFi. Profile plot showing the percentage of CpGs having opposite methylation changes between disease development (i.e. RA vs controls) and the response to TNFi (i.e. week12 vs baseline) for the pathways linked with RA. The top 40 pathways showing the strongest significant statistical evidence are included in the plot. These results confirm the effect of blood methylation variation induced by TNFi, clearly reversing it towards that of healthy individuals.CC BY-NC-ND · PubMed Central
Figure 6 Transcription factors associated with the response to TNFi in monocytes. Using motif-enrichment analysis on the CpG sites associated with TNFi response in monocytes, we identified multiple transcription factors significantly associated with the regulatory changes. A 500 bp region centered around the associated CpG sites in monocytes was used in the analysis. Analysis of differentially methylated positions (DMPs) was performed separately for hypermethylated and hypomethylated CpGs in responders. The motif enrichment score for each transcription factor family (TF) is depicted as a horizontal line; at the end of each line, the significance of the TF association is represented as the diameter of the circle.
Figure 6 Transcription factors associated with the response to TNFi in monocytes. Using motif-enrichment analysis on the CpG sites associated with TNFi response in monocytes, we identified multiple transcription factors significantly associated with the regulatory changes. A 500 bp region centered around the associated CpG sites in monocytes was used in the analysis. Analysis of differentially methylated positions (DMPs) was performed separately for hypermethylated and hypomethylated CpGs in responders. The motif enrichment score for each transcription factor family (TF) is depicted as a horizontal line; at the end of each line, the significance of the TF association is represented as the diameter of the circle.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 43

  1. Myasoedova, 2010, Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007, Arthritis Rheum, 62, 1576, 10.1002/art.27425 · DOI
  2. Felson, 2011, American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials, Ann Rheum Dis, 70, 404, 10.1136/ard.2011.149765 · DOI
  3. Pitzalis, 2020, Transforming clinical trials in rheumatology: towards patient-centric precision medicine, Nat Rev Rheumatol, 16, 590, 10.1038/s41584-020-0491-4 · DOI
  4. Bergman, 2020, Clinical utility and cost savings in predicting inadequate response to Anti-TNF therapies in rheumatoid arthritis, Rheumatol Ther, 7, 775, 10.1007/s40744-020-00226-3 · DOI
  5. Taylor, 2009, Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nat Rev Rheumatol, 5, 578, 10.1038/nrrheum.2009.181 · DOI
  6. Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 · DOI
  7. Martin-Mola, 2016, Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review, Rheumatol Int, 36, 1043, 10.1007/s00296-016-3506-3 · DOI
  8. Acosta-Colman, 2013, GWAS replication study confirms the association of PDE3A–SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis, Pharmacogenomics, 14, 727, 10.2217/pgs.13.60 · DOI
  9. Julià, 2009, An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis, PLoS One, 4, e7556, 10.1371/journal.pone.0007556 · DOI
  10. Lequerré, 2006, Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis, Arthritis Res Ther, 8, 1, 10.1186/ar1990 · DOI
  11. Sekiguchi, 2008, Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-α monoclonal antibody, infliximab, Rheumatology, 47, 780, 10.1093/rheumatology/ken083 · DOI
  12. Kim, 2017, DNA methylation: an epigenetic mark of cellular memory, Exp Mol Med, 49, e322, 10.1038/emm.2017.10 · DOI · Paper page
  13. Karouzakis, 2018, Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis, Sci Rep, 8, 7370, 10.1038/s41598-018-24240-2 · DOI
  14. Ai, 2015, DNA methylome signature in synoviocytes from patients with early rheumatoid arthritis compared to synoviocytes from patients with longstanding rheumatoid arthritis, Arthritis Rheumatol, 67, 1978, 10.1002/art.39123 · DOI
  15. Li Yim, 2021, Novel insights into rheumatoid arthritis through characterization of concordant changes in DNA methylation and gene expression in synovial biopsies of patients with differing numbers of swollen joints, Front Immunol, 12, 1215, 10.3389/fimmu.2021.651475 · DOI
  16. Liu, 2013, Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis, Nat Biotechnol, 31, 142, 10.1038/nbt.2487 · DOI
  17. Rodríguez-Ubreva, 2019, Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis, Ann Rheum Dis, 78, 1505, 10.1136/annrheumdis-2019-215355 · DOI
  18. Ballestar, 2017, New insights into the epigenetics of inflammatory rheumatic diseases, Nat Rev Rheumatol, 13, 593, 10.1038/nrrheum.2017.147 · DOI
  19. Glossop, 2017, DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis, Epigenomics, 9, 419, 10.2217/epi-2016-0042 · DOI
  20. Zheng, 2018, Identification of differentially methylated cell types in epigenome-wide association studies, Nat Methods, 15, 1059, 10.1038/s41592-018-0213-x · DOI
  21. Aterido, 2019, Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis, Ann Rheum Dis, 78, 355, 10.1136/annrheumdis-2018-214158 · DOI
  22. Fransen, 2009, The disease activity score and the EULAR response criteria, Rheum Dis Clin North Am, 35, 745, 10.1016/j.rdc.2009.10.001 · DOI
  23. Rubbert-Roth, 2020, Trial of upadacitinib or abatacept in rheumatoid arthritis, N Engl J Med, 383, 1511, 10.1056/NEJMoa2008250 · DOI · Paper page
  24. Triche Jr, 2013, Low-level processing of Illumina Infinium DNA methylation beadarrays, Nucleic Acids Res, 41, e90, 10.1093/nar/gkt090 · DOI
  25. Ritchie, 2015, limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, 43, e47, 10.1093/nar/gkv007 · DOI · Paper page
  26. Phipson, 2016, missMethyl: an R package for analyzing data from Illumina's HumanMethylation450 platform, Bioinformatics, 32, 286, 10.1093/bioinformatics/btv560 · DOI
  27. Maksimovic, 2015, Removing unwanted variation in a differential methylation analysis of Illumina HumanMethylation450 array data, Nucleic Acids Res, 43, e106, 10.1093/nar/gkv526 · DOI
  28. Maksimovic, 2021, Gene set enrichment analysis for genome-wide DNA methylation data, Genome Biol, 22, 1, 10.1186/s13059-021-02388-x · DOI
  29. You, 2020, A cell-type deconvolution meta-analysis of whole blood EWAS reveals lineage-specific smoking-associated DNA methylation changes, Nat Commun, 11, 4779, 10.1038/s41467-020-18618-y · DOI
  30. Houseman, 2012, DNA methylation arrays as surrogate measures of cell mixture distribution, BMC Bioinformatics, 13, 1, 10.1186/1471-2105-13-86 · DOI · Paper page
  31. Plant, 2016, Differential methylation as a biomarker of response to etanercept in patients with rheumatoid arthritis, Arthritis Rheumatol, 68, 1353, 10.1002/art.39590 · DOI
  32. Tao, 2021, Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis, Arthritis Rheumatol, 73, 212, 10.1002/art.41516 · DOI
  33. Plant, 2012, Replication of association of the PTPRC gene with response to anti–tumor necrosis factor therapy in a large UK cohort, Arthritis Rheum, 64, 665, 10.1002/art.33381 · DOI
  34. Julià, 2020, Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis, Arthritis Res Ther, 22, 196, 10.1186/s13075-020-02287-9 · DOI
  35. Tasaki, 2018, Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission, Nat Commun, 9, 1, 10.1038/s41467-018-05044-4 · DOI
  36. El Masri, 2021, RHO GTPases: from new partners to complex immune syndromes, Nat Rev Immunol, 1
  37. van, 2012, Rho GTPase expression in human myeloid cells, PLOS ONE, 7, e42563, 10.1371/journal.pone.0042563 · DOI
  38. Saci, 2005, RhoA GTPase regulates B cell receptor signaling, Mol Cell, 17, 205, 10.1016/j.molcel.2004.12.012 · DOI
  39. Tackenberg, 2020, The Small GTPase Cdc42 is a major regulator of neutrophil effector functions, Front Immunol, 11, 1197, 10.3389/fimmu.2020.01197 · DOI
  40. Boyle, 2015, The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis, Ann Rheum Dis, 74, 1311, 10.1136/annrheumdis-2014-206028 · DOI
  41. Xue, 2020, CD14+ CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK, Arthritis Res Ther, 22, 1, 10.1186/s13075-020-02308-7 · DOI
  42. Marzaioli, 2021, CD209/CD14+ dendritic cells characterization in rheumatoid and psoriatic arthritis patients: activation, synovial infiltration, and therapeutic targeting, Front Immunol, 12
  43. Dulic, 2017, T-cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy, Mediators Inflamm, 2017

Cited by

Sorted by citations

Metadata

Authors
Julià, A., Gómez, A., López-Lasanta, M., Blanco, F., Erra, A., Fernández-Nebro, A., Mas, A. J., Pérez-García, C., Vivar, M. L. G., Sánchez-Fernández, S., Alperi-López, M., Sanmartí, R., Ortiz, A. M., Fernandez-Cid, C. M., Díaz-Torné, C., Moreno, E., Li, T., Martínez-Mateu, S. H., Absher, D. M., Myers, R. M., Molina, J. T., & Marsal, S.
ORCID
Venue
eBioMedicine
Publisher
Elsevier BV
Published
2022-06
Volume
80
Pages
104053
ISSN
2352-3964
DOI
10.1016/j.ebiom.2022.104053
PMC
PMC9118662
Cited by
24
References
1
Language
en
Licence
Funders
Instituto de Salud Carlos III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review